Infliximab – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:23 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Infliximab – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Infliximab Market 2021-2025 https://www.cri-report.com/report-on-chinas-infliximab-market-2021-2025/ Fri, 21 May 2021 06:26:47 +0000 https://www.cri-report.com/?post_type=product&p=11423 CRI analyzes that China's Infliximab market will keep a growth trend from 2021 to 2025 due to price reduction. After the patent for Infliximab expired, more biosimilar drugs have appeared on the market.

The post Investigation Report on China’s Infliximab Market 2021-2025 first appeared on CRI Report.

]]> China’s Infliximab Market

Infliximab is a human-mouse chimeric IgG1 monoclonal antibody targeting tumor necrosis factor (TNF-α) (composed of human IgG1 constant region and mouse variable region). It is used to treat a variety of autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis.

Infliximab was developed by Johnson & Johnson. In 2007, Infliximab entered the Chinese market. By 2020, Janssen Biologics BV is the only manufacturer in the Chinese Infliximab market.

According to CRI’s market research, since Infliximab entered the Chinese market in 2007, its sales have had an increasing trend. However, the sales in China are suboptimal compared to global sales. The main reason is that most patients in China cannot afford the expensive price.

After Infliximab was included in the national medical insurance in 2019, the sales increased about 18.86% in 2020 and reached CNY213.7 million. The CAGR for Infliximab is approximately 14.65% from 2016 to 2020.

CRI analyzes that the sales of Infliximab will keep a growth trend from 2021 to 2025 due to price reduction. After the patent for Infliximab expired, more biosimilar drugs have appeared in the market.

In China, three companies have already submitted applications for Infliximab in 2019 and 2020. Therefore, in the next few years, the market share for Janssen Biologics BV will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Infliximab.

Topics Covered:
-The impact of COVID-19 on China’s Infliximab market
– Sales value of China’s Infliximab 2016-2020
– Competitive landscape of China’s Infliximab market
– Prices of Infliximab in China
– Prices of Infliximab in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Infliximab market
– Prospect of China’s Infliximab market from 2021 to 2025

Investigation Report on China’s Infliximab Market, 2018-2022

The post Investigation Report on China’s Infliximab Market 2021-2025 first appeared on CRI Report.

]]> Investigation Report on China’s Infliximab Market, 2018-2022 https://www.cri-report.com/investigation-report-on-chinas-infliximab-market-2018-2022/ Thu, 25 Oct 2018 05:38:45 +0000 https://www.cri-report.com/product/import-placeholder-for-1809340/ Description By 2017, there were over 5 million rheumatoid arthritis (RA) patients and over 4 million ankylosing spondylitis patients in China. As the incidence of Crohn’s disease rises in recent years, over 100,000 people in China suffer from this disease every year. Infliximab is a human-mouse chimeric monoclonal antibody that works against tumor necrosis factor alpha (TNF-α). By identifying, binding and blocking TNF-α, the drug reduces the inflammations caused by TNF-α, relieves symptoms, and inhibits joint tissue damages and bone erosion. Developed by Johnson & Johnson, in Oct. 1998, Infliximab…

The post Investigation Report on China’s Infliximab Market, 2018-2022 first appeared on CRI Report.

]]> Description
By 2017, there were over 5 million rheumatoid arthritis (RA) patients and over 4 million ankylosing spondylitis patients in China. As the incidence of Crohn’s disease rises in recent years, over 100,000 people in China suffer from this disease every year.
Infliximab is a human-mouse chimeric monoclonal antibody that works against tumor necrosis factor alpha (TNF-α). By identifying, binding and blocking TNF-α, the drug reduces the inflammations caused by TNF-α, relieves symptoms, and inhibits joint tissue damages and bone erosion.
Developed by Johnson & Johnson, in Oct. 1998, Infliximab was first launched in the trade name of Remicade in the U.S. for the treatment of moderate to severe Crohn’s disease.
On Sept. 1, 2007, Xi’an Janssen Pharmaceutical Ltd., a Chinese subsidiary of Johnson & Johnson, announced the launch of Remicade in China. Infliximab has been approved by the CFDA to treat rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease.
By Oct. 2018, China’s Infliximab market is monopolized by Remicade imported by Xi’an Janssen Pharmaceutical Ltd. In 2017, the sales value of Infliximab was about CNY 167 million in China.
According to CRI, the sales value has been increasing since Infliximab came into the Chinese market. However, high prices make the drug unaffordable for many low-income patients. In 2017, Infliximab was included in the List of Medicines Covered by National Basic Medical Insurance, which will drive up the sales value.

Topics Covered:
– Situation of rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease in China
– Sales of Infliximab in China
– Prices of Infliximab in China
– Forecast on China’s Infliximab market from 2018 to 2022

The post Investigation Report on China’s Infliximab Market, 2018-2022 first appeared on CRI Report.

]]>